Lixudebart RENAL Phase 2 analysis
CSL’s October 2026 partnership identifies lixudebart, formerly ALE.F02, in the ongoing RENAL Phase 2 AAV-RPGN study. Claudin-1 targeting is intended to address inflammatory/fibrotic kidney injury.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Private-company classification is explicitly supported by CSL’s October 5, 2026 partnership announcement, which calls Alentis privately held; recheck before activation.
- Alentis licensing status is not the same as CSL ownership; no undisclosed payment is used as settlement evidence.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Phase 2 primary analysis — date unconfirmed
Company context
An official company source identifies the company as privately held. This is source-reported context, not independent legal-registry verification; recheck ownership, listing and acquisition status before any market listing.
Potential outcome market
Will the full prespecified primary analysis of lixudebart’s RENAL Phase 2 study be publicly reported by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.